• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

融合蛋白G3G6和HST1致敏DC疫苗抗黑色素瘤的药效学研究

王睿, 王永梅, 蔡铭君, 柯学佳, 吴越, 崇军, 曹荣月

王睿, 王永梅, 蔡铭君, 柯学佳, 吴越, 崇军, 曹荣月. 融合蛋白G3G6和HST1致敏DC疫苗抗黑色素瘤的药效学研究[J]. 中国药科大学学报, 2019, 50(2): 238-245. DOI: 10.11665/j.issn.1000-5048.20190216
引用本文: 王睿, 王永梅, 蔡铭君, 柯学佳, 吴越, 崇军, 曹荣月. 融合蛋白G3G6和HST1致敏DC疫苗抗黑色素瘤的药效学研究[J]. 中国药科大学学报, 2019, 50(2): 238-245. DOI: 10.11665/j.issn.1000-5048.20190216
shu
WANG Rui, WANG Yongmei, CAI Mingjun, KE Xuejia, WU Yue, CHONG Jun, CAO Rongyue. Pharmacological effects of anti-melanoma DC vaccine sensitized by fusion proteins of G3G6 and HST1[J]. Journal of China Pharmaceutical University, 2019, 50(2): 238-245. DOI: 10.11665/j.issn.1000-5048.20190216
Citation: WANG Rui, WANG Yongmei, CAI Mingjun, KE Xuejia, WU Yue, CHONG Jun, CAO Rongyue. Pharmacological effects of anti-melanoma DC vaccine sensitized by fusion proteins of G3G6 and HST1[J]. Journal of China Pharmaceutical University, 2019, 50(2): 238-245. DOI: 10.11665/j.issn.1000-5048.20190216
shu

融合蛋白G3G6和HST1致敏DC疫苗抗黑色素瘤的药效学研究

  • 1.

    中国药科大学生命科学与技术学院

  • 2.

    上海复星长征医学科学有限公司

基金项目: 国家基础科学人才培养基金资助项目(No.J1310032)；国家自然科学基金资助项目(No.81373232,No.81673340)；江苏高校优势学科建设工程资助项目(PAPD)

Pharmacological effects of anti-melanoma DC vaccine sensitized by fusion proteins of G3G6 and HST1

摘要

    摘要
  • 摘要: 探究促性腺激素释放激素(GnRH)与胃泌素释放肽(GRP)偶联的融合蛋白(G3G6)和热休克蛋白65(HSP65)与六跨膜前列腺上皮抗原(STEAP1)偶联的融合蛋白(HST1)致敏树突状细胞(DC)的效果和致敏后DC对B16F10黑色素瘤的抑制杀伤作用。利用实验室现存工程菌表达融合蛋白G3G6和HST1，按未致敏DC(US-DC)组，G3G6融合蛋白致敏DC(G3G6-DC)组，HST1融合蛋白致敏DC(HST1-DC)组和G3G6及HST1联合致敏DC(GH-DC)组致敏小鼠骨髓来源的DC分化成熟，获得融合蛋白致敏的相应DC疫苗。将B16F10黑色素瘤细胞以1×106个/只移植于C57BL/6J雄性小鼠构建黑色素瘤模型，DC疫苗免疫治疗，体内外实验探究DC疫苗的抗肿瘤药效。流式细胞术分析证明，融合蛋白有效刺激DC分化成熟；动物实验显示，与US-DC组相比，G3G6-DC黑色素瘤抑制率为35.75%，HST1-DC组为34.03%，GH-DC组为55.74%。研究结果初步证明，G3G6-DC和HST1-DC均可有效抑制黑色素瘤B16F10细胞小鼠移植瘤的生长(P<；0.05)，且联合用药优于单独用药(P<；0.01)。
    Abstract: This study aimed to investigate the effects of fusion proteins GnRH-GRP(G3G6)and HSP65-STEAP1(HST1)on dendritic cells(DC)and the sensitization of DCs to B16F10 melanoma. The fusion proteins G3G6 and HST1 were obtained using the previous engineering strains in our laboratory. Group by unsensitized DC(US-DC), the G3G6 fusion protein sensitized DC, the HST1 fusion protein sensitized DC(HST1-DC)and the combined sensitized DC(GH-DC), the mouse bone marrow-derived DCs were sensitized with fusion protein to obtain the fusion protein sensitized DC vaccines. B16F10 melanoma cells were transplanted into C57BL/6J male mice to construct a melanoma model(1×106 cells per mouse), and DC vaccine was injected for treatment. The antitumor efficacy of DC vaccine was explored by in vitro and in vivo experiments. Flow cytometry analysis showed that the fusion protein can effectively stimulate DC into differentiation and maturation; in the animal experiment, the inhibition rate of melanoma treated with G3G6-DC was 35. 75%, that of HST1-DC group and combination group were 34. 03% and 55. 74%. It was initially proved that both G3G6-DC and HST1-DC can effectively inhibit the growth of transplanted tumors of melanoma B16F10 cells in mice, and the combination therapy is superior to the single therapy.
    • HTML全文
    • 参考文献(32)
  • [1] Yang LG.Immunotherapy for malignant melanoma:current status and progress [J].Chin Cancer(中国肿瘤),2018,27(1):54-60.
    [2] Wang HY,Lu J.Progress in clinical research of tumor immunotherapy[J].The J Pract Med(实用医学杂志),2018,34(6):917-919.
    [3] Diao AP,Zhao Q.Research progress in immune cell-mediated cancer therapy[J].J Tianjin Univ Sci Technol(天津科技大学学报),2018,33(1):1-8.
    [4] Chen JH,Zhao DQ.Research progress in immune escape mechanism [J].J Hyg Res(卫生研究),2018,47(2):330-334.
    [5] Chen DW,Wang Y,Wang H,et al.CD8+ T activation attenuates CD4+ T proliferation through dendritic cells modification[J].Cell Immunol,2015,296(2):138-148.
    [6] Berner VK,duPre SA,Redelman D,et al.Microparticulate β-glucan vaccine conjugates phagocytized by dendritic cells activate both naive CD4 and CD8 T cells in vitro[J].Cell Immunol,2015,298(1/2):104-114.
    [7] Liu SJ,Xie QY,Gong FS,et al.Efficacy of dendritic and cytokine-induced killer cells on postoperative patients with malignant melanoma[J].J Fujian Med Univ(福建医科大学学报),2017,51(4):17-22.
    [8] Zheng YM,He CC,Wang SZ,et al.Effect of co-culturing dendritic cells with melanoma cells on formation of melanoma in mice[J].Shandong Med J(山东医药),2017,57(5):1-3.
    [9] Jia PY,Wang YX.Gonadotropin releasing hormone and its receptor associated with tumor therapy:research advances[J].J Int Pharm Res(国际药学研究杂志),2009,36(3):179-183.
    [10] Zhang Y,Liu XX,Wang R,et al.Comparison of fusion protein and dc vaccine in inhibition of mouse b16f10 melanoma tumor[J].Biomed Pharmacother,2018,97:784-792.
    [11] Lu Y,Zhang HY,Hou J,et al.Vaccination with a potent DNA vaccine targeting B-cell epitopes of hGRP induces prophylactic and therapeutic antitumor activity in vivo[J].Gene Ther,2010,17(4):459-468.
    [12] Gulley JL,Madan RA,Tsang KY,et al.Immune impact induced by prostvac(psa-tricom),a therapeutic vaccine for prostate cancer[J].Cancer Immunol Res,2014,2(2):133-141.
    [13] Gomes IM,Maia CJ,Santos CR.STEAP proteins:from structure to applications in cancer therapy[J].Mol Cancer Res,2012,10(5):573-587.
    [14] Maia CJ,Socorro S,Schmitt F,et al.STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland[J].Endocrine,2008,34(1/2/3):108-116.
    [15] Cheung IY,Feng Y,Danis K,et al.Novel markers of subclinical disease for Ewing family tumors from gene expression profiling[J].Clin Cancer Res,2007,13(23):6978-6983.
    [16] Moreaux J,Kassambara A,Hose D,et al.STEAP1 is overexpressed in cancers:a promising therapeutic target[J].Biochem Biophys Res Commun,2012,429(3/4):148-155.
    [17] Kobayashi H,Nagato T,Sato K,et al.Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner[J].Cancer Res,2007,67(11):5498-5504.
    [18] Garcia-Hernandez Mde L,Gray A,Hubby B,et al.In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate:a candidate antigen for treating prostate cancer[J].Cancer Res,2007,67(3):1344-1351.
    [19] Wowk PF,Franco LH,Fonseca DMD,et al.Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients[J].Hum Vacc Immunother,2017,13:1-11.
    [20] Wang XJ,Gu K,Xu JS,et al.Immunization with a recombinant GnRH vaccine fused to heat shock protein 65 inhibits mammary tumor growth in vivo[J].Cancer Immunol Immunother,2010,59(12):1859-1866.
    [21] Skalova K,Mollova K,Michalek J.Human myeloid dendritic cells for cancer therapy:does maturation matter[J]?Vaccine,2010,28(32):5153-5160.
    [22] Zhang CY,Liu JY,Zhang ZM,et al.Study on the optimal efficient ratio on target cells and the antitumor activity of effect cells stimulated by dendritic cells in vitro[J].J Guangxi Med Univ(广西医科大学学报),2007,24(4):493-496.
    [23] Zhang Y,Liu XX,Wang R,et al.Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor[J].Biomed Pharmacother,2018,97:784-792.
    [24] Liu SJ,Wei XF,Liu SF,et al.In vitro anti-tumor effect of mGM-CSF-GnRH3 and mGM-CSF-GRP6 recombinant fusion protein and their bioinformatics prediction[J].Chin J Cancer Biother(中国肿瘤生物治疗杂志),2018,25(6):582-589.
    [25] Jing LL,Miao ZT,Li MM,et al.Anti-tumor effect and its mechanism of co-administration of fusion proteins hVEGF121/βhCG and mGM-CSF/βhCG[J].J China Pharm Univ(中国药科大学学报),2017,48(1):102-109.
    [26] Cao RY,Yu MX,Zhang XL,et al.Construction,expression,purification of VEGF II/GRP fusion protein and the effects on RM-1 prostate tumor in mice[J].J Chin Biotechnol(中国生物工程杂志),2016,36(8):9-15.
    [27] Li MM,Jing LL,Yuan YT,et al.Inhibitory effect of hVEGF_(121)/βHCG fusion protein combined with chemical drugs on mouse B16F10 melanoma [J].Chin J Pharm Biotechnol(药物生物技术),2016,23(4):299-303.
    [28] Jing LL,Zhang XL,Li MM,et al.Effect of GnRH/M2 and mGM-CSF/βhCG fusion protein-sensitized dendritic cell vaccine against mouse prostate cancer [J].Cancer Res Prev Treat(肿瘤防治研究),2016,43(10):842-847.
    [29] Cao RY,Ma YF,Yuan YT,et al.Inhibitory effect of DC vaccine sensitized by GnRH/M2 fusion protein on melanoma B16F10 cell xenografts[J].Chin J Cancer Biother(中国肿瘤生物治疗杂志),2016,23(4):468-475.
    [30] Cao XT.New advances in basic and clinical research of dendritic cells[J].Chin J Immunol(中国免疫学杂志),1998,14(3):167-168.
    [31] Zhong GC.New advances in enhancing antigen presentation by dendritic cells[J].Chin J Cell Mol Immunol(细胞与分子免疫学杂志),2004,20(2):253-256.
    [32] Henrickson SE,Mempel TR,Mazo IB,et al.OR.30.T Cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation[J].Nat Immunol,2008,9(3):282-291.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  864
  • HTML全文浏览量:  1
  • PDF下载量:  862
  • 被引次数: 0
出版历程
  • 刊出日期:  2019-04-24

目录

摘要
HTML全文
    参考文献(32)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336184

    x 关闭 永久关闭